Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Presentations to Highlight Corporate and Clinical Progress
CORALVILLE, Iowa, March 06, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following investor conferences during the month of March.
Details of KemPharm's presentations are as follows:
| Event: | Cowen and Company 38th Annual Health Care Conference 2018 | |
| Date: | Monday, March 12, 2018 | |
| Time: | 12:00 PM (ET) | |
| Location: | The Boston Marriott Copley Place, Boston, MA | |
| Room: | Regis | |
| Event: | 29th Annual ROTH Conference | |
| Date: | March 13, 2018 | |
| Time: | 11:30 AM (PT) | |
| Location: | The Ritz Carlton, Dana Point, CA | |
| Room: | Blue – Salon 2 | |
| Event: | Oppenheimer & Co. 28th Annual Healthcare Conference | |
| Date: | March 20, 2018 | |
| Time: | 10:20 AM (ET) | |
| Location: | The Westin New York Grand Central, New York, NY | |
| Room: | Track 3 |
All presentation webcasts will be available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/ following delivery at the respective conferences.
About KemPharm:
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition, the company has received FDA approval for Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both Apadaz and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
| Investor Contacts: | Media Contact: |
| Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] | Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected] |
